Home > Newsletters > FDAnews Drug Daily Bulletin > FTC Cheers As Reverse Patent Settlement Deemed Anticompetitive on Appeal
FDAnews Drug Daily Bulletin
July 25, 2012 | Vol. 9 No. 145
FTC Cheers As Reverse Patent Settlement Deemed Anticompetitive on Appeal
The FTC’s fight against what it calls “pay-for-delay” settlements received a boost Monday when the Third Circuit Court of Appeals reversed a lower court ruling that had upheld a reverse patent settlement. The Third Circuit rejected most arguments from Upsher-Smith Laboratories and Schering-Plough, saying their 1998 settlement on potassium deficiency drug K-Dur 20 (potassium chloride) was anticompetitive.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.